ANALYSIS: 5 things to know about the Oxford-AstraZeneca vaccine

ANALYSIS: 5 things to know about the Oxford-AstraZeneca vaccine

Cheap and easy to store, the Oxford-AstraZeneca vaccine approved by the British regulator on Wednesday has given a shot in the arm to the global fight against coronavirus.

Here are five facts about the much-anticipated vaccine:


The Oxford-AstraZeneca vaccine has the major advantages of being inexpensive, costing about £2.50 per dose, and easy to store.

It can be kept at normal refrigerator temperatures of between two and eight degrees Celsius, making it ideal for large-scale vaccination programmes.

By contrast, the Moderna vaccine needs to be stored at -20C, while the Pfizer/BioNTech product must be kept at -70C.


The vaccine should be capable of fighting the new variant of the coronavirus responsible for a surge of cases in the United Kingdom, according to AstraZeneca chief executive Pascal Soriot.

"So far, we think the vaccine should remain effective. But we can't be sure, so we're going to test that," he told the Sunday Times.

New versions are being developed just in case, he revealed, adding: "You have to get prepared."


The vaccine developed by British firm AstraZeneca, working alongside Oxford University, is the second to be approved by the independent Medicines and Healthcare products Regulatory Agency (MHRA).

The Pfizer/BioNTech vaccine has been deployed in Britain since 8 December, with almost 800,000 receiving their first dose, according to British Prime Minister Boris Johnson.

His government is battling one of the world's worst outbreaks, with more than 71,000 deaths so far of those testing positive for the disease.

Britain has ordered 100 million doses of the Oxford-AstraZeneca vaccine, 40 million of which will be available by the end of March, with vaccinations scheduled to begin on 4 January.

AstraZeneca said it expects to be able to manufacture about three billion doses of its vaccine worldwide in 2021.


The vaccine is "virus-vectored", meaning it is a version of a virus that normally infects chimpanzees and has been modified with a portion of the COVID-19 coronavirus called the "spike protein" to fire the immune system.

Once in human cells, the vaccine should help stimulate the production of antibodies that recognise the virus.

The vaccine is "safe and effective", according to data published by The Lancet medical journal on 8 December, with only one of the 23,754 volunteers who participated in the trials experiencing "possibly-related severe side effects".

This was a case of rare neurological condition transverse myelitis that forced the temporary suspension of trials.


The British laboratory announced in interim findings in November that its vaccine was on average 70% effective, compared with more than 90% for Pfizer/BioNTech and Moderna.

The efficacy of the Oxford-AstraZeneca vaccine was 90% for volunteers who first received only a half-dose and then a full dose one month later, but only 62% for another group that was vaccinated with two full doses one month apart.

The injection of a half-dose was conducted by accident, raising criticism over the robustness of the results and prompting the company to announce on 26 November that an "additional study" would be held into the efficacy of the reduced dosage.

"We think we have figured out the winning formula and how to get efficacy that, after two doses, is up there with everybody else," Soriot told the Sunday Times.

Download the EWN app to your iOS or Android device.